DANVERS, Mass--(BUSINESS WIRE)--
The hemodynamic support of Abiomed’s (ABMD) Impella heart pump platform for high-risk PCI and treatment of cardiogenic shock will be highlighted in more than 30 presentations and posters at the American College of Cardiology’s (ACC) 68th Annual Scientific Session March 16-18, in New Orleans.
Impella is the only FDA approved, safe and effective heart pump for high-risk PCI, cardiogenic shock, and right ventricular failure, and has supported more than 100,000 patients in the United States, Germany and Japan. Abiomed remains committed to advancing the field of heart recovery through clinical research and support, education, and innovation. Impella will be featured at ACC with:
- Presentations of Clinical Data
- Team-Based Treatment of Cardiogenic Shock: A case-based session chaired by Perwaiz Meraj, MD and Alexander Truesdell, MD will highlight the benefits of multidisciplinary management of cardiogenic shock including the use of best practices such as placing Impella before PCI.
- Kidney Protection with Impella: An analysis by Michael Flaherty, MD from the ongoing, prospective cVAD study shows an 85.5% lower incidence rate of AKI during high-risk PCI when Impella is used (n=233, p<0.0001).
- Peripartum Cardiomyopathy: Uri Elkayam, MD will present a poster presentation on the use of Impella heart pump for management of women with peripartum cardiogenic shock.
- Interactive Learning at Abiomed’s Booth
Abiomed’s booth #129 will feature clinical data and hands-on learning with the Impella platform including Impella with SmartAssist and Impella Connect, which provide advanced technology and 24x7 clinical support services to improve patient outcomes. Abiomed’s pipeline products including Impella 5.5™, Impella ECP™, Impella BTR™, and expandable sheath1 will be included. Abiomed’s simulation training tool will allow attendees to experience Impella CP heart pump insertion, placement, and management.
- Potential Live High-Risk PCI Case Using the Impella Heart Pump
Protected PCI with Impella improves quality of life and reduces post-discharge major adverse cardiovascular and cerebrovascular events (MACCE) by 47% at 90 days2. Abiomed anticipates the potential broadcast of an elective live Protected PCI case from Beth Israel Deaconess Medical Center utilizing Impella during the conference.
For more information about Abiomed and heart recovery, visit www.abiomed.com.
1. The Impella 5.5™ heart pump is not approved for use or sale in the U.S. Impella ECP™ and Impella BTR™ heart pumps, and the expandable sheath are in development and are not approved for use or sale.
2. O’Neill WW et al. Circulation. PROTECT II Randomized Controlled Trial. 2012 Oct 2:126(14):1717-27.
ABOUT IMPELLA HEART PUMPS
The Impella 2.5 and Impella CP devices are FDA approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI) such as stenting or balloon angioplasty, to re-open blocked coronary arteries. The Impella 2.5®, Impella CP®, Impella CP® with SmartAssist, Impella 5.0® and Impella LD® are FDA approved heart pumps used to treat heart attack or cardiomyopathy patients in cardiogenic shock, and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart. To learn more about the Impella platform of heart pumps, including their approved indications and important safety and risk information associated with the use of the devices, please visit: www.protectedpci.com.
The ABIOMED logo, ABIOMED, Impella, Impella 2.5, Impella 5.0, Impella LD, Impella CP, Impella RP, Impella Connect, and Recovering hearts. Saving lives. are registered trademarks of ABIOMED, Inc. in the U.S. and in certain foreign countries.
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com.
This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.